2. Search Result
Search Result
Results for "

chronic Hepatitis B

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

1

Isotope-Labeled Compounds

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121513
    Torcitabine

    2'-Deoxy-L-cytidine; L-dC

    		 HBV Infection
    Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment .
    Torcitabine
  • HY-114314
    BA-53038B

    		HBV Infection
    BA-53038B is a HBV core protein allosteric modulator (CpAM), binding to the HAP pocket and modulating HBV capsid assembly. BA-53038B has antiviral activity for hepatitis B virus (HBV) with an EC50 value of 3.32 μM. BA-53038B can be used for the research of chronic hepatitis B .
    BA-53038B
  • HY-W018791
    Bifendate

    DDB

    		 HBV Autophagy Cytochrome P450 Atg8/LC3 p62 P-glycoprotein Infection Cardiovascular Disease Cancer
    Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) .
    Bifendate
  • HY-115430
    Tenofovir disoproxil aspartate

    		HIV Reverse Transcriptase HBV Infection
    Tenofovir disoproxil aspartate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B .
    Tenofovir disoproxil aspartate
  • HY-P4051
    HBV Seq1 aa:141-151

    		HBV Infection Inflammation/Immunology
    HBV Seq1 aa:141-151 is a peptide. HBV Seq1 aa:141-151 can be used for the research of chronic hepatitis B virus (HBV) .
    HBV Seq1 aa:141-151
  • HY-P99541
    Tuvirumab

    anti-Hepatitis B; OST 577; SDZ-OST 577

    		 HBV Infection
    Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
    Tuvirumab
  • HY-113586
    Besifovir Dipivoxil

    LB-80380

    		 Others Infection
    Besifovir Dipivoxil (LB-80380), an analog of guanosine monophosphate, is an acyclic nucleotide phosphonate with antiviral effect. Besifovir Dipivoxil is rapidly converted by the liver and intestine to the intermediate metabolite LB80331 via the esterification process, subsequently phosphorylated into the di- and triphosphate forms, which act as antiviral DNA synthesis inhibitors. Besifovir Dipivoxil is promising for research of chronic hepatitis B .
    Besifovir Dipivoxil
  • HY-159903
    TQL-1055

    		Influenza Virus Infection
    TQL-1055 is a semi-synthetic analog of the saponin adjuvant QS-21 (HY-101092) and can be used as a prophylactic vaccine adjuvant. TQL-1055 exhibits robust adjuvant activity for influenza antigens. TQL-1055 combined with the acellular pertussis vaccine (aP) shows good tolerance and enhances the antibody response to pertussis toxin (PT) in mice and rabbits. TQL-1055 is promising for research of chronic hepatitis B .
    TQL-1055
  • HY-145638
    Xalnesiran

    		HBV Infection
    Xalnesiran is siRNA for the treatment of chronic hepatitis B (HBV).
    Xalnesiran
  • HY-145638A
    Xalnesiran sodium

    		HBV Infection
    Xalnesiran (sodium) is siRNA for the treatment of chronic hepatitis B (HBV)..
    Xalnesiran sodium
  • HY-13910A
    Tenofovir hydrate
    Maximum Cited Publications
    7 Publications Verification

    GS 1278 hydrate; PMPA hydrate

    		 HIV Reverse Transcriptase Infection Cancer
    Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
    Tenofovir hydrate
  • HY-13910B
    Tenofovir maleate

    GS 1278 maleate; PMPA maleate

    		 HIV Reverse Transcriptase Infection Cancer
    Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
    Tenofovir maleate
  • HY-13782
    Tenofovir Disoproxil fumarate
    Maximum Cited Publications
    7 Publications Verification

    Tenofovir DF; Bis(POC)-PMPA fumarate; GS 4331 fumarate

    		 HIV Reverse Transcriptase HBV Infection
    Tenofovir Disoproxil fumarate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.
    Tenofovir Disoproxil fumarate
  • HY-13910
    Tenofovir
    Maximum Cited Publications
    7 Publications Verification

    GS 1278; PMPA

    		 Reverse Transcriptase HIV HBV Infection Cancer
    Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .
    Tenofovir
  • HY-13782A
    Tenofovir Disoproxil
    Maximum Cited Publications
    7 Publications Verification

    Bis(POC)-PMPA; GS 4331

    		 HIV Reverse Transcriptase HBV Cancer
    Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
    Tenofovir Disoproxil
  • HY-103487
    Uprifosbuvir

    IDX21437; MK-3682

    		 HCV Infection
    Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus .
    Uprifosbuvir
  • HY-168165
    Adefovir diphosphate

    		Others Cancer
    Adefovir diphosphate is an antiviral compound with activity against hepatitis B virus (HBV). Adefovir diphosphate blocks the replication of HBV by inhibiting reverse transcriptase. Adefovir diphosphate has also shown activity against other viruses such as herpes viruses and human immunodeficiency virus. Adefovir diphosphate is used as an effective inhibitory option in the suppression of chronic hepatitis B. The mechanism of action of Adefovir diphosphate involves blocking the autophosphorylation of growth factor receptors, thereby potentially reducing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B .
    Adefovir diphosphate
  • HY-19447A
    Besifovir Dipivoxil maleate

    LB80380 maleate

    		 HBV Infection
    Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies [2]
    Besifovir Dipivoxil maleate
  • HY-13910AR
    Tenofovir (hydrate) (Standard)

    		HIV Reverse Transcriptase Infection
    Tenofovir (hydrate) (Standard) is the analytical standard of Tenofovir (hydrate). This product is intended for research and analytical applications. Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
    Tenofovir (hydrate) (Standard)
  • HY-W074930
    (S)-Tenofovir

    (S)-GS 1278; (S)-PMPA; (S)-TDF

    		 HIV HBV Infection
    (S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .
    (S)-Tenofovir
  • HY-147255
    Canocapavir

    ZM-H1505R

    		 HBV Infection
    Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B. .
    Canocapavir
  • HY-113904S
    (Rac)-Tenofovir-d6

    		Reverse Transcriptase HIV HBV Infection
    (Rac)-Tenofovir-d6 is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV)[1].
    (Rac)-Tenofovir-d6
  • HY-162795
    HBV-IN-47

    		HBV Infection
    HBV-IN-47 (compound 4a) is a capsid assembly regulator with inhibitory activity against hepatitis B virus (HBV). HBV-IN-47 exhibits strong anti-HBV activity in HepAD38 cells with low toxicity (EC50=0.24 μM). HBV-IN-47 can be used for the study of chronic hepatitis B (CHB) .
    HBV-IN-47
  • HY-137453
    Tenofovir amibufenamide

    HS-10234

    		 HBV Infection
    Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study .
    Tenofovir amibufenamide
  • HY-13782R
    Tenofovir Disoproxil fumarate (Standard)

    Tenofovir DF (Standard); Bis(POC)-PMPA fumarate (Standard); GS 4331 fumarate (Standard)

    		 HIV Reverse Transcriptase HBV Infection
    Tenofovir Disoproxil (fumarate) (Standard) is the analytical standard of Tenofovir Disoproxil (fumarate). This product is intended for research and analytical applications. Tenofovir Disoproxil fumarate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.
    Tenofovir Disoproxil fumarate (Standard)
  • HY-13910R
    Tenofovir (Standard)

    		Reverse Transcriptase HIV HBV Infection Cancer
    Tenofovir (Standard) is the analytical standard of Tenofovir. This product is intended for research and analytical applications. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .
    Tenofovir (Standard)
  • HY-124600
    NVR 3-778
    1 Publications Verification

    		 HBV Infection
    NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity .
    NVR 3-778
  • HY-106235
    LB80317

    		HBV DNA/RNA Synthesis Infection
    LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC50 of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment .
    LB80317
  • HY-147255A
    (S)-Canocapavir

    (S)-ZM-H1505R

    		 Others Infection
    (S)-Canocapavir is the isomer of Canocapavir (HY-147255A). Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B .
    (S)-Canocapavir
  • HY-W074930R
    (S)-Tenofovir (Standard)

    		HIV HBV Infection
    (S)-Tenofovir (Standard) is the analytical standard of (S)-Tenofovir. This product is intended for research and analytical applications. (S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV) .
    (S)-Tenofovir (Standard)
  • HY-148768
    AB-506

    		HBV Inflammation/Immunology
    AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research .
    AB-506
  • HY-15256A
    Faldaprevir sodium

    BI 201335 sodium

    		 HCV Protease Infection
    Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .
    Faldaprevir sodium
  • HY-15256
    Faldaprevir

    BI 201335

    		 HCV Protease Infection
    Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .
    Faldaprevir
  • HY-145713A
    GS-8873 TFA

    HBV-IN-19 TFA

    		 HBV Infection
    GS-8873 TFA is the TFA salt form of GS-8873 (HY-145713). GS-8873 TFA is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 TFA exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 TFA causes neurofunctional deficits in rats and cynomolgus monkeys .
    GS-8873 TFA
  • HY-145713
    GS-8873

    HBV-IN-19

    		 HBV Infection
    GS-8873 is an orally active inhibitor for the production of hepatitis B virus (HBV) surface antigen (HBsAg) with an EC50 of 4 nM. GS-8873 exhibits good pharmacokinetic characters in rats and metabolic stability in human hepatocytes. GS-8873 causes neurofunctional deficits in rats and cynomolgus monkeys .
    GS-8873
  • HY-151134
    HBV-IN-25

    		HBV Infection
    HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA＞452 μg/mL) and good PK property with no cellular toxicity .
    HBV-IN-25
  • HY-W352344
    2'-Deoxy-L-adenosine

    		HBV Infection
    2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV) .
    2'-Deoxy-L-adenosine
  • HY-W105601
    5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine

    2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine

    		 Others Infection
    5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine (2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine) is an antiviral compound that inhibits HBV reverse transcriptase activity. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine shows potential to control HBV replication in vitro. 5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine, as a nucleoside analog, may provide a new option for the suppression of chronic hepatitis B .
    5'-Deoxy-2',3'-di-O-acetyl-5-fluorocytidine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: